AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. KNSA
  4. [Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity

[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

Insider transactions by Thomas Malley, a director of Kiniksa Pharmaceuticals International, plc (KNSA) are reported for August 12鈥�14, 2025. The Form 4 shows multiple option exercises and open-market sales. Mr. Malley exercised stock options at strike prices ranging from $1.86 to $15.47, converting options into Class A ordinary shares. The filing reports open-market sales totaling 207,898 shares sold across three days at weighted-average sale prices in the low $30s (individual weighted averages reported at $32.4, $33.32 and $33.09). After these transactions, Mr. Malley directly beneficially owned 12,546 Class A shares and indirectly beneficially owned 71,967 shares through Mossrock Capital, LLC. The filing notes all reported options are fully vested and exercisable and includes broker execution price ranges for the sales.

Operazioni di insider di Thomas Malley, amministratore di Kiniksa Pharmaceuticals International, plc (KNSA) registrate per il periodo 12鈥�14 agosto 2025. Il Form 4 riporta pi霉 esercizi di opzioni e vendite sul mercato aperto. Malley ha esercitato opzioni con prezzi di esercizio compresi tra $1,86 e $15,47, convertendole in azioni ordinarie di Classe A. La documentazione segnala vendite sul mercato aperto per un totale di 207.898 azioni vendute in tre giorni a prezzi medi ponderati nella fascia dei 30 dollari (medie ponderate singole riportate: $32,40, $33,32 e $33,09). Dopo queste operazioni, Malley deteneva direttamente 12.546 azioni di Classe A e indirettamente 71.967 azioni tramite Mossrock Capital, LLC. Il filing specifica che tutte le opzioni riportate sono completamente maturate ed esercitabili e include gli intervalli dei prezzi di esecuzione dei broker per le vendite.

Transacciones internas de Thomas Malley, director de Kiniksa Pharmaceuticals International, plc (KNSA) reportadas para el 12鈥�14 de agosto de 2025. El Formulario 4 muestra m煤ltiples ejercicios de opciones y ventas en mercado abierto. Malley ejerci贸 opciones con precios de ejercicio entre $1.86 y $15.47, convirti茅ndolas en acciones ordinarias Clase A. La presentaci贸n informa ventas en mercado abierto por un total de 207,898 acciones vendidas en tres d铆as a precios promedio ponderados en los bajos $30 (promedios ponderados individuales: $32.4, $33.32 y $33.09). Tras estas operaciones, Malley pose铆a directamente 12,546 acciones Clase A e indirectamente 71,967 acciones a trav茅s de Mossrock Capital, LLC. El filing indica que todas las opciones informadas est谩n totalmente devengadas y ejercitables e incluye los rangos de precios de ejecuci贸n de los brokers para las ventas.

Kiniksa Pharmaceuticals International, plc (KNSA) 鞚挫偓 Thomas Malley鞚� 雮措秬鞛� 瓯半灅臧� 2025雲� 8鞗� 12鈥�14鞚检瀽搿� 氤搓碃霅橃棃鞀惦媹雼�. Form 4鞐愲姅 鞐煬 彀鞚� 鞀ろ啞鞓奠厴 頄夓偓鞕� 瓿店皽鞁滌灔 毵り皝鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟. Malley電� 頄夓偓臧�瓴� $1.86鞐愳劀 $15.47 靷澊鞚� 鞓奠厴鞚� 頄夓偓頃橃棳 鞚措ゼ 韥措灅鞀� A 氤错喌欤茧 鞝勴櫂頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� 瓿店皽鞁滌灔 毵る弰電� 齑� 3鞚� 霃欖晥 207,898欤� 毵り皝鞙茧 歆戧硠霅橃棃瓿�, 臧�欷戫弶攴� 毵る弰臧�瓴╈潃 30雼煬 齑堧皹雽�(臧滊硠 臧�欷戫弶攴�: $32.4, $33.32, $33.09)鞓�鞀惦媹雼�. 頃措嫻 瓯半灅 頉� Malley電� 歆侅爲鞝侅溂搿� 12,546欤� 韥措灅鞀� A毳�, Mossrock Capital, LLC毳� 韱淀暣 臧勳爲鞝侅溂搿� 71,967欤�毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滊電� 氤搓碃霅� 氇摖 鞓奠厴鞚� 鞕勳爠頌� 氩犾姢韺呺悩鞏� 頄夓偓 臧�電ロ暔鞚� 氇呾嫓頃橂┌, 毵り皝鞐� 雽�頃� 欷戧皽 鞁ろ枆 臧�瓴� 氩旍渼霃� 韽暔頃橁碃 鞛堨姷雼堧嫟.

Op茅rations d'initi茅 de Thomas Malley, administrateur de Kiniksa Pharmaceuticals International, plc (KNSA), rapport茅es pour la p茅riode du 12 au 14 ao没t 2025. Le formulaire 4 fait 茅tat de plusieurs exercices d'options et de ventes sur le march茅 ouvert. M. Malley a exerc茅 des options avec des prix d'exercice allant de $1,86 脿 $15,47, les convertissant en actions ordinaires de Classe A. Le d茅p么t rapporte des ventes sur le march茅 ouvert totalisant 207 898 actions vendues sur trois jours 脿 des prix de vente moyens pond茅r茅s dans les bas $30 (moyennes pond茅r茅es individuelles : $32,40, $33,32 et $33,09). Apr猫s ces op茅rations, M. Malley d茅tenait directement 12 546 actions de Classe A et indirectement 71 967 actions via Mossrock Capital, LLC. Le document pr茅cise que toutes les options d茅clar茅es sont enti猫rement acquises et exer莽ables et inclut les fourchettes de prix d'ex茅cution des courtiers pour les ventes.

Insider-Transaktionen von Thomas Malley, Direktor von Kiniksa Pharmaceuticals International, plc (KNSA), gemeldet f眉r den Zeitraum 12.鈥�14. August 2025. Das Formular 4 weist mehrere Optionsaus眉bungen und Verk盲ufe am offenen Markt aus. Herr Malley 眉bte Aktienoptionen mit Aus眉bungspreisen zwischen $1,86 und $15,47 aus und wandelte diese in Class-A-Stammaktien um. Die Einreichung meldet Verk盲ufe am offenen Markt in H枚he von insgesamt 207.898 verkauften Aktien 眉ber drei Tage zu gewichteten Durchschnittspreisen in den niedrigen $30ern (einzelne gewichtete Durchschnitte: $32,40, $33,32 und $33,09). Nach diesen Transaktionen besa脽 Herr Malley direkt 12.546 Class-A-Aktien und indirekt 71.967 Aktien 眉ber Mossrock Capital, LLC. Die Meldung weist darauf hin, dass alle angegebenen Optionen vollst盲ndig unverfallbar und aus眉bbar sind und enth盲lt die Ausf眉hrungspreisbereiche der Broker f眉r die Verk盲ufe.

Positive
  • None.
Negative
  • Large open-market sales: Reporting person sold a significant number of shares across 08/12/2025鈥�08/14/2025 totaling 207,898 shares at weighted-average prices reported in the low $30s.
  • Reduced direct ownership: After transactions, direct beneficial ownership falls to 12,546 Class A ordinary shares, which may be viewed negatively by some investors.
  • Concentrated timing: Multiple sales occurred immediately after option exercises over a three-day window, which can raise questions about the timing and motive for liquidity.

Insights

Director sold a large block of shares following option exercises; creates governance and signaling questions for investors.

The filing documents substantial open-market sales by a company director executed immediately after exercising vested options. Sales of over 200,000 shares at weighted-average prices in the low $30s materially reduce the director's direct stake to 12,546 shares while leaving indirect holdings via Mossrock Capital, LLC. From a governance perspective, clustered insider sales tied to option exercises can be routine liquidity events but may also be perceived negatively by market participants unless accompanied by an explanation. The filing provides execution price ranges and confirms options were fully vested, which supports the mechanics of the transactions but does not explain timing or purpose.

Substantial exercised options and subsequent sales increased free float; impact depends on context and company size.

The report shows multiple option exercises across six strike prices from $1.86 to $15.47, with corresponding open-market sales at ~ $32鈥�$33 per share. The exercised option amounts listed in Table II total 157,769 underlying shares and the reported non-derivative sales aggregate 207,898 shares across three trading dates. These transactions elevated supply sold into the market and left the reporting person with limited direct ownership but meaningful indirect holdings through Mossrock. Without company-wide share count context or concurrent corporate developments, the market impact is ambiguous; the activity is material in absolute terms but its effect on valuation requires total outstanding shares and trading volume data not present in this filing.

Operazioni di insider di Thomas Malley, amministratore di Kiniksa Pharmaceuticals International, plc (KNSA) registrate per il periodo 12鈥�14 agosto 2025. Il Form 4 riporta pi霉 esercizi di opzioni e vendite sul mercato aperto. Malley ha esercitato opzioni con prezzi di esercizio compresi tra $1,86 e $15,47, convertendole in azioni ordinarie di Classe A. La documentazione segnala vendite sul mercato aperto per un totale di 207.898 azioni vendute in tre giorni a prezzi medi ponderati nella fascia dei 30 dollari (medie ponderate singole riportate: $32,40, $33,32 e $33,09). Dopo queste operazioni, Malley deteneva direttamente 12.546 azioni di Classe A e indirettamente 71.967 azioni tramite Mossrock Capital, LLC. Il filing specifica che tutte le opzioni riportate sono completamente maturate ed esercitabili e include gli intervalli dei prezzi di esecuzione dei broker per le vendite.

Transacciones internas de Thomas Malley, director de Kiniksa Pharmaceuticals International, plc (KNSA) reportadas para el 12鈥�14 de agosto de 2025. El Formulario 4 muestra m煤ltiples ejercicios de opciones y ventas en mercado abierto. Malley ejerci贸 opciones con precios de ejercicio entre $1.86 y $15.47, convirti茅ndolas en acciones ordinarias Clase A. La presentaci贸n informa ventas en mercado abierto por un total de 207,898 acciones vendidas en tres d铆as a precios promedio ponderados en los bajos $30 (promedios ponderados individuales: $32.4, $33.32 y $33.09). Tras estas operaciones, Malley pose铆a directamente 12,546 acciones Clase A e indirectamente 71,967 acciones a trav茅s de Mossrock Capital, LLC. El filing indica que todas las opciones informadas est谩n totalmente devengadas y ejercitables e incluye los rangos de precios de ejecuci贸n de los brokers para las ventas.

Kiniksa Pharmaceuticals International, plc (KNSA) 鞚挫偓 Thomas Malley鞚� 雮措秬鞛� 瓯半灅臧� 2025雲� 8鞗� 12鈥�14鞚检瀽搿� 氤搓碃霅橃棃鞀惦媹雼�. Form 4鞐愲姅 鞐煬 彀鞚� 鞀ろ啞鞓奠厴 頄夓偓鞕� 瓿店皽鞁滌灔 毵り皝鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟. Malley電� 頄夓偓臧�瓴� $1.86鞐愳劀 $15.47 靷澊鞚� 鞓奠厴鞚� 頄夓偓頃橃棳 鞚措ゼ 韥措灅鞀� A 氤错喌欤茧 鞝勴櫂頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� 瓿店皽鞁滌灔 毵る弰電� 齑� 3鞚� 霃欖晥 207,898欤� 毵り皝鞙茧 歆戧硠霅橃棃瓿�, 臧�欷戫弶攴� 毵る弰臧�瓴╈潃 30雼煬 齑堧皹雽�(臧滊硠 臧�欷戫弶攴�: $32.4, $33.32, $33.09)鞓�鞀惦媹雼�. 頃措嫻 瓯半灅 頉� Malley電� 歆侅爲鞝侅溂搿� 12,546欤� 韥措灅鞀� A毳�, Mossrock Capital, LLC毳� 韱淀暣 臧勳爲鞝侅溂搿� 71,967欤�毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滊電� 氤搓碃霅� 氇摖 鞓奠厴鞚� 鞕勳爠頌� 氩犾姢韺呺悩鞏� 頄夓偓 臧�電ロ暔鞚� 氇呾嫓頃橂┌, 毵り皝鞐� 雽�頃� 欷戧皽 鞁ろ枆 臧�瓴� 氩旍渼霃� 韽暔頃橁碃 鞛堨姷雼堧嫟.

Op茅rations d'initi茅 de Thomas Malley, administrateur de Kiniksa Pharmaceuticals International, plc (KNSA), rapport茅es pour la p茅riode du 12 au 14 ao没t 2025. Le formulaire 4 fait 茅tat de plusieurs exercices d'options et de ventes sur le march茅 ouvert. M. Malley a exerc茅 des options avec des prix d'exercice allant de $1,86 脿 $15,47, les convertissant en actions ordinaires de Classe A. Le d茅p么t rapporte des ventes sur le march茅 ouvert totalisant 207 898 actions vendues sur trois jours 脿 des prix de vente moyens pond茅r茅s dans les bas $30 (moyennes pond茅r茅es individuelles : $32,40, $33,32 et $33,09). Apr猫s ces op茅rations, M. Malley d茅tenait directement 12 546 actions de Classe A et indirectement 71 967 actions via Mossrock Capital, LLC. Le document pr茅cise que toutes les options d茅clar茅es sont enti猫rement acquises et exer莽ables et inclut les fourchettes de prix d'ex茅cution des courtiers pour les ventes.

Insider-Transaktionen von Thomas Malley, Direktor von Kiniksa Pharmaceuticals International, plc (KNSA), gemeldet f眉r den Zeitraum 12.鈥�14. August 2025. Das Formular 4 weist mehrere Optionsaus眉bungen und Verk盲ufe am offenen Markt aus. Herr Malley 眉bte Aktienoptionen mit Aus眉bungspreisen zwischen $1,86 und $15,47 aus und wandelte diese in Class-A-Stammaktien um. Die Einreichung meldet Verk盲ufe am offenen Markt in H枚he von insgesamt 207.898 verkauften Aktien 眉ber drei Tage zu gewichteten Durchschnittspreisen in den niedrigen $30ern (einzelne gewichtete Durchschnitte: $32,40, $33,32 und $33,09). Nach diesen Transaktionen besa脽 Herr Malley direkt 12.546 Class-A-Aktien und indirekt 71.967 Aktien 眉ber Mossrock Capital, LLC. Die Meldung weist darauf hin, dass alle angegebenen Optionen vollst盲ndig unverfallbar und aus眉bbar sind und enth盲lt die Ausf眉hrungspreisbereiche der Broker f眉r die Verk盲ufe.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Malley Thomas
(Last) (First) (Middle)
23 OLD BOND STREET, THIRD FLOOR
(Street)
LONDON X0 W1S 4PZ
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Ordinary Shares 08/12/2025 M 21,959 A $1.86 34,505 D
Class A Ordinary Shares 08/12/2025 M 27,448 A $3.8 61,953 D
Class A Ordinary Shares 08/12/2025 S 49,407 D $32.4(1) 12,546 D
Class A Ordinary Shares 08/13/2025 M 20,129 A $10.36 32,675 D
Class A Ordinary Shares 08/13/2025 M 30,000 A $9.88 62,675 D
Class A Ordinary Shares 08/13/2025 S 50,129 D $33.32(2) 12,546 D
Class A Ordinary Shares 08/14/2025 M 18,760 A $15.47 31,306 D
Class A Ordinary Shares 08/14/2025 M 33,237 A $14.33 64,543 D
Class A Ordinary Shares 08/14/2025 M 26,236 A $15.19 90,779 D
Class A Ordinary Shares 08/14/2025 S 78,233 D $33.09(3) 12,546 D
Class A Ordinary Shares 71,967 I See footnote(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Share Option $1.86 08/12/2025 M 21,959 (5) 12/06/2026 Class A Ordinary Shares 21,959 $0 0 D
Share Option $3.8 08/12/2025 M 27,448 (5) 06/28/2027 Class A Ordinary Shares 27,448 $0 0 D
Share Option $10.36 08/13/2025 M 20,129 (5) 02/29/2028 Class A Ordinary Shares 20,129 $0 0 D
Share Option $9.88 08/13/2025 M 30,000 (5) 06/28/2032 Class A Ordinary Shares 30,000 $0 0 D
Share Option $15.47 08/14/2025 M 18,760 (5) 05/28/2029 Class A Ordinary Shares 18,760 $0 0 D
Share Option $14.33 08/14/2025 M 33,237 (5) 06/28/2031 Class A Ordinary Shares 33,237 $0 0 D
Share Option $15.19 08/14/2025 M 26,236 (5) 06/04/2033 Class A Ordinary Shares 26,236 $0 0 D
Explanation of Responses:
1. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.06 and $32.685. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $33.1301 and $33.50. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.82 and $33.41. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
4. Mr. Malley is the president of Mossrock Capital, LLC (Mossrock) and may be deemed to beneficially own the shares owned by Mossrock.
5. The option is fully vested and exercisable.
/s/ Madelyn Zeylikman, Attorney-in-Fact 08/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What transactions did Thomas Malley (KNSA) report on Form 4?

He exercised multiple vested stock options and sold shares in open-market transactions between 08/12/2025 and 08/14/2025.

How many KNSA shares were sold by the reporting person and at what prices?

207,898 shares were sold across the reported dates at weighted-average sale prices reported at $32.4, $33.32, and $33.09 (with execution ranges provided in the filing).

What is Thomas Malley鈥檚 ownership in Kiniksa after these transactions?

Directly owns 12,546 Class A ordinary shares and indirectly beneficially owns 71,967 shares through Mossrock Capital, LLC, per the filing.

Were the options exercised by Malley vested and exercisable?

Yes. The filing states each reported option is fully vested and exercisable.

Are price details for the sales available?

Yes. The filing provides weighted-average prices for reported sales and discloses execution price ranges for each sale in the explanation section.
Stock KNSA logo
Kiniksa Pharmaceuticals International, plc

NASDAQ:KNSA

KNSA Rankings

#1899 Ranked by Market Cap
N/A Ranked by Dividends

KNSA Latest News

Aug 28, 2025
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
Jul 29, 2025
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
Jul 24, 2025
Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July聽29, 2025
Jun 5, 2025
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
May 29, 2025
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

KNSA Latest SEC Filings

Aug 20, 2025
[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity
Aug 18, 2025
[144] Kiniksa Pharmaceuticals International, plc SEC Filing
Aug 14, 2025
[144] Kiniksa Pharmaceuticals International, plc SEC Filing
Aug 13, 2025
[144] Kiniksa Pharmaceuticals International, plc SEC Filing
Aug 12, 2025
[144] Kiniksa Pharmaceuticals International, plc SEC Filing

KNSA Stock Data

2.49B
41.84M
3.68%
93.03%
3.28%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United Kingdom
LONDON